NIH study: MOUD in prison reduces relapse and reincarceration

This title was summarized by AI from the post below.

A study supported by NIH finds that individuals who received medication for opioid use disorder (MOUD) while incarcerated were significantly more likely to continue treatment six months after release than those who did not receive MOUD, and were less likely to be reincarcerated. #RecoveryMonth Read more here ➡️ https://t.co/QpBJvbiQCF

  • Quote from Nora D. Volkow, M.D., Director of the National Institute on Drug Abuse (NIH), emphasizing the significance of providing corrections settings with effective opioid treatment to aid in recovery and reduce reincarceration. The background is blue with the NIH logo on the right.

💡 Such important findings! Providing access to MOUD during incarceration not only supports recovery but also builds a stronger pathway back into community life. 🌱 A step forward in reducing reincarceration and giving people the tools they need for long-term healing.

Absolutely. I have said for several years, the American DOC; is full of drugs. Not only full of drugs, the dealers are always home. Dealers need a mandatory minimum sentence, the addicts need rehab, and trade education. You must take the head off the snake. #justicereform #rehabilitationbeforeincarceration

Thomas P. Cargiulo, PharmD, BCMAS

Pharmacist with over 35 years experience in the substance use disorder field.

4w

The lack of MOUD during incarceration is one example of the institutional inflicted trauma that occurs to individuals in jails and prisons. This trauma is carried back to the communities and inhibit a person's ability to heal, thrive and live with dignity.

Like
Reply
Madelyn Cooper

Staff Research Associate at UCLA Integrated Substance Use and Addiction Programs

1mo

Hello, I'm hoping that just about anybody will find this. I've conducted some lived experience research on Neurofibromatosis as a person living with NF. Please, God, somebody with common sense and compassion read and help us. https://www.linkedin.com/posts/madelyn--cooper_neurofibromatosis-breaking-the-spontaneous-activity-7373454042058039298-cyrW?utm_source=share&utm_medium=member_desktop&rcm=ACoAACr8zn8BEsKh4_ij4fGIs8QbooJ4ck9_Vao

Like
Reply
Dr. Richard Gadomski MD MS

CEO / CMO, Co-Founder, Taos Therapeutics: innovative Alcohol Use Disorder care via agonist & aversive agent plus smart delivery device = first in class therapeutic modality which humanely addresses the neurobiology.

1mo

Without MOUD during incarceration, immediately upon release the risk of fatal overdose - statistically speaking - is absolutely staggering. Not only are burprenorphine and methadone harm reduction, they are essential life saving medicines necessary to combat the devastating overdose epidemic in our country

Like
Reply
Kristy Mitchell

Certified Alcohol & Other Drug Supervisor l Counselor | Helping People Build Lasting Recovery | Motivating Change Through Compassion & Accountability

4w

This is slowly being introduced to the DOC I work at. All paper mail will be available on their tablets as well, reducing the illegal flow of drug traffic. Our DOC offers a drug treatment program. It is effective in reducing the recidivism rate, hoping the introduction of MOUD is effective as well.

Like
Reply
See more comments

To view or add a comment, sign in

Explore content categories